

CBCS Scheme

USN

--	--	--	--	--	--	--	--	--	--

16/17BBT252

Second Semester M.Tech. Degree Examination, June/July 2018 Clinical Biotechnology

Time: 3 hrs.

Max. Marks: 80

Note: Answer any FIVE full questions, choosing one full question from each module.

Module-1

- 1 a. Explain double blind and single blind randomized controlled trials. (08 Marks)
b. Compare Cohort studies with taking prospective and retrospective Cohort time. (08 Marks)

OR

- 2 a. Write short notes on: i) Case control study ii) Nested case control study. (08 Marks)
b. Explain about informed consent related to clinical trials. (08 Marks)

Module-2

- 3 a. Discuss the steps to be followed for conducting clinical trials. (08 Marks)
b. Write about parallel group design and its significance. (08 Marks)

OR

- 4 a. Explain any one statistical application software used for data management. (08 Marks)
b. Breakdown the steps in clinical data management. (08 Marks)

Module-3

- 5 a. Explain about therapeutic proteins and its applications. (08 Marks)
b. Discuss the role of anticoagulants and significance in clinical biotechnology. (08 Marks)

OR

- 6 Short notes on:
a. Interleukins
b. Streptokinase
c. Bacteriostatic agents
d. Neuromuscular blocking agent. (16 Marks)

Module-4

- 7 a. Explain the positive and negative aspects in radiotherapy and chemotherapy with examples. (08 Marks)
b. Write a detailed note on clinical toxicology. (08 Marks)

OR

- 8 a. What are the procedures followed by human system in biotransformation of toxins. (08 Marks)
b. Write short note on: i) Hepatotoxicity ii) Nephrotoxicity. (08 Marks)

Module-5

- 9 a. Compare the advantages and draw backs of conventional pharmaceuticals and neutraceuticals. (08 Marks)
b. What are the GCP to be followed in a drug development lab? (08 Marks)

OR

- 10 a. Infer on the clinical trial guidelines set by government of India. (08 Marks)
b. Explain risk assessment and trial monitoring in clinical trials. (08 Marks)

* * * * *

Important Note : 1. On completing your answers, compulsorily draw diagonal cross lines on the remaining blank pages.
2. Any revealing of identification, appeal to evaluator and /or equations written eg. 42+8 = 50, will be treated as malpractice.